NEW YORK – Qiagen said after the close of the market on Thursday that it has acquired the remaining approximately 80 percent of diagnostics developer NeuMoDx Molecular that it did not already own for $248 million in cash.
NEW YORK – Qiagen said after the close of the market on Thursday that it has acquired the remaining approximately 80 percent of diagnostics developer NeuMoDx Molecular that it did not already own for $248 million in cash.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.
Privacy Policy. Terms & Conditions. . Copyright © 2021 GenomeWeb, a business unit of Crain Communications. All Rights Reserved.